Claims
- 1. A composition comprising an active ingredient and a .gamma.-cyclodextrin ether or mixed ether wherein the ether substituents are C.sub.1 -C.sub.6 alkyl, hydroxy C.sub.1 -C.sub.6 alkyl, carboxy C.sub.1 -C.sub.6 alkyl or (C.sub.1 -C.sub.6 alkyloxycarbonyl)C.sub.1 -C.sub.6 alkyl; provided that neither methyl nor hydroxypropyl is a sole substituent.
- 2. A composition according to claim 1 wherein the ether substituents are C.sub.1 -C.sub.3 alkyl, hydroxy C.sub.2 -C.sub.4 alkyl or carboxy C.sub.1 -C.sub.2 alkyl.
- 3. A composition according to claim 1 wherein the ether substituents are methyl, ethyl, isopropyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxymethyl or carboxyethyl.
- 4. A composition comprising an active ingredient and a .gamma.-cyclodextrin ether or mixed ether wherein the ether substituents are C.sub.1 -C.sub.3 alkyl, hydroxy C.sub.2 -C.sub.4 alkyl or carboxy C.sub.1 -C.sub.2 alkyl and wherein the degree of substitution is in the range of 0.125 to less than 2.
- 5. A composition according to claim 4 wherein the ether substituent is hydroxyethyl or hydroxypropyl and the average molar substitution is in the range of 0.3 to less than one.
- 6. A composition according to claim 1, wherein the active ingredient is a drug.
- 7. A composition according to claim 4, wherein the active ingredient is a drug.
- 8. A composition according to claim 5, wherein the active ingredient is a drug.
- 9. A composition according to claim 6, wherein the drug is a non-steroid anti-rheumatic agent, a steroid, a cardiac glycoside or a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 10. A composition according to claim 7, wherein the drug is a non-steroid anti-rheumatic agent, a steroid, a cardiac glycoside or a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 11. A composition according to claim 8, wherein the drug is a non-steroid anti-rheumatic agent, a steroid, a cardiac glycoside or a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 12. A composition according to claim 6, wherein the drug is a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 13. A composition according to claim 7, wherein the drug is a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 14. A composition according to claim 8, wherein the drug is a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 15. A composition according to claim 6, wherein the drug is selected from the group consisting of etomidate, ketoconazole, itraconazole and flunarizine.
- 16. A composition according to claim 7, wherein the drug is selected from the group consisting of etomidate, ketoconazole, itraconazole and flunarizine.
- 17. A composition according to claim 8, wherein the drug is selected from the group consisting of etomidate, ketoconazole, itraconazole and flunarizine.
- 18. A composition according to claim 4, wherein the active ingredient is a drug.
- 19. A composition according to claim 18, wherein the drug is a non-steroid anti-rheumatic agent, a steroid, a cardiac glycoside or a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 20. A composition according to claim 18, wherein the drug is a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4,-triazinedione, 2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole or hydratropic acid, or an amide or trialkylamine derivative.
- 21. A composition according to claim 4, wherein the drug is a derivative of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, 1,2,4-triazinedione, 2,3,5,6-tetrahydra-imidazo[2,1-b]thiazole or hydratropc acid, or an amide or trialkylamine derivative.
- 22. A composition according to claim 4, wherein the drug is selected from the group consisting of etomidate, ketoconazole, itraconazole and flunarizine.
- 23. A method of preparing a composition according to claim 1, characterized in that the .gamma.-cyclodextrin ether is dissolved in water and that the active ingredient is added whereafter the thus obtained solution is optionally dried.
- 24. A method of preparing a composition according to claim 2 characterized in that the .gamma.-cyclodextrin ether is dissolved in water and that the active ingredient is added whereafter the thus obtained solution is optionally dried.
- 25. A method of preparing a composition according to claim 4 characterized in that the .gamma.-cyclodextrin ether is dissolved in water and that the active ingredient is added whereafter the thus obtained solution is optionally dried.
- 26. A method according to claim 23, wherein the residue after removal of the solvent is pulverized and, optionally after addition of further ingredients, converted into a solid form for administration.
- 27. A method according to claim 26, wherein further physiologically acceptable substances are added to the water.
- 28. A method according to claim 27, wherein sodium chloride, glucose, mannitol, sorbitol, xylitol or a phosphate or citrate buffer are added to the water.
- 29. A method according to claim 24, wherein the residue after removal of the solvent is pulverized and, optionally after addition of further ingredients, converted into a solid form for administration.
- 30. A method according to claim 29, wherein further physiologically acceptable substances are added to the water.
- 31. A method according to claim 30, wherein sodium chloride, glucose, mannitol, sorbitol, xylitol or a phosphate or citrate buffer are added to the water.
Parent Case Info
This is a division of application Ser. No. 833,622, filed Feb. 27, 1986, now U.S. Pat. No. 4,764,604, issued Aug. 16, 1988.
US Referenced Citations (11)
Foreign Referenced Citations (5)
Number |
Date |
Country |
1548917 |
Oct 1968 |
FRX |
57-200361 |
Jun 1981 |
JPX |
144376 |
Feb 1982 |
JPX |
138473 |
Dec 1985 |
JPX |
122701 |
Nov 1986 |
JPX |
Non-Patent Literature Citations (3)
Entry |
Enhanced Water Solubility of Vitamins A,D,E, and K, by Substituted Cycloamyloses; Life Sciences, vol. 29, pp. 307-311 Printed in USA. |
The Chemistry of Cyclodextrin Derivatives; I.Int. Symp. on Cyclodextrins Budapest, 1981. |
Windholz et al, The Merck Index, an encyclopedia of chemicals, drugs, and biologicals, Tenth Edition, Published by Merck & Co., Inc., Rahway, N.J., pp. 560, 592, 753 and 762 (1983). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
833622 |
Feb 1986 |
|